Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004863 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00004863 is a Phase 1 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT00004863, a Phase 1 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of paclitaxel and GEM 231 in treating patients who have recurrent or refractory solid tumors.
Interventions
- DRUG paclitaxel
- DRUG GEM 231
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1999-07 |
| Est. Completion | 2001-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004863
The ClinicalTrials.gov registry entry for NCT00004863 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00004863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004863 about?
NCT00004863 is a clinical study titled "Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of paclitaxel and GEM 231 in treating patients who have recurrent or refr...
What is the current status of trial NCT00004863?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1999-07. Estimated completion is 2001-08.
What interventions are being tested in trial NCT00004863?
The interventions under investigation include: paclitaxel (DRUG), GEM 231 (DRUG).
Who is sponsoring clinical trial NCT00004863?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.